This site is intended for health professionals only
Wednesday 19 December 2018
Share |

First patient randomised in study evaluating safety and efficacy of anakinra in Still’s disease

Swedish Orphan Biovitrum AB has announced that the first patient has been randomised in the Phase III study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatment of Still’s disease.


The purpose of the study is to assess the efficacy and to evaluate the safety of anakinra in patients with newly diagnosed Still’s disease, including systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD). The anaSTILLs study is a randomised, double-blind, multicentre study being conducted in North America studying two dose levels of anakinra, administrated subcutaneously, in comparison to placebo. In total 81 individuals are planned to be randomised in the study.


We are very pleased with having initiated this confirmatory clinical study investigating the safety and efficacy of anakinra in people with Still’s disease. This is a disease affecting both young people and adults and is associated with a significant morbidity and with a large unmet medical need,” says Milan Zdravkovic, Senior Vice President, Chief Medical Officer and Head of Research & Development at Sobi.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher